ImmunityBio, Inc.
NASDAQIBRX utilization hits 100%, availability plunges to 0.19% — borrow market effectively exhausted.
ImmunityBio has hit a new inflection point this week — the borrow market, already tight heading into the June 9 earnings release, has effectively run dry, even as the stock dropped 7% over the past five days to…
IBRX enters its June 9 earnings release with a lending market that has rarely been looser than "very tight." Availability has dropped to just 6.2% — meaning fewer than seven shares remain available to borrow for every…
Snapshot as of 21 Jun 2026
ImmunityBio heads into its June 9 earnings report caught between two opposing forces: options traders have turned sharply bullish on a three-day basis, yet a deeply entrenched short position covering more than a third…
ImmunityBio enters its May 8 earnings call navigating a securities fraud lawsuit, a wave of class-action filings over alleged drug promotion violations, and 14% of its float shorted — a combination that makes the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for IBRX — free to start on ORTEX.
Sign up for free →Open IBRX on ORTEX